Online first
Original article
Published online: 2024-11-13
Long-term outcome, mortality predictors and cardiac-device related infective endocarditis in patients with surgically corrected valvular versus non-valvular heart failure treated with cardiac resynchronization therapy
Abstract
Not available
References
- Anand IS, Carson P, Galle E, et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation. 2009; 119(7): 969–977.
- Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352(15): 1539–1549.
- Tang ASL, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010; 363(25): 2385–2395.
- Sipahi I, Carrigan TP, Rowland DY, et al. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. Arch Intern Med. 2011; 171(16): 1454–1462.
- Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. Am Heart J. 2012; 163(2): 260–267.e3.
- Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011; 123(10): 1061–1072.
- Arshad A, Moss AJ, Foster E, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011; 57(7): 813–820.
- Boriani G, Gasparini M, Landolina M, et al. Effectiveness of cardiac resynchronization therapy in heart failure patients with valvular heart disease: comparison with patients affected by ischaemic heart disease or dilated cardiomyopathy. The InSync/InSync ICD Italian Registry. Eur Heart J. 2009; 30(18): 2275–2283.
- Leyva F, Umar F, Taylor RJ, et al. The clinical outcome of cardiac resynchronization therapy in post-surgical valvular cardiomyopathy. Europace. 2016; 18(5): 732–738.
- Bose A, Upadhyay GA, Kandala J, et al. Does prior valve surgery change outcome in patients treated with cardiac resynchronization therapy? J Cardiovasc Electrophysiol. 2014; 25(11): 1206–1213.
- Macías A, Gavira JJ, Castaño S, et al. Cardiac resynchronization therapy and valvular cardiomyopathy after corrective surgery. Rev Esp Cardiol. 2008; 61(10): 1088–1091.
- Piccini JP, Passman R, Turakhia M, et al. Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices. Europace. 2019; 21(3): 404–413.
- Wilton SB, Leung AA, Ghali WA, et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: A systematic review and meta-analysis. Heart Rhythm. 2011; 8(7): 1088–1094.
- Gupta S, Belley-Cote EP, Sarkaria A, et al. International normalized ratio targets for left-sided mechanical valve replacement. Thromb Haemost. 2018; 118(5): 906–913.
- Poli D, Antonucci E, Pengo V, et al. Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. Int J Cardiol. 2018; 267: 68–73.
- Scheggi V, Merilli I, Marcucci R, et al. Predictors of mortality and adverse events in patients with infective endocarditis: A retrospective real world study in a surgical centre. BMC Cardiovasc Disord. 2021; 21(1): 28.
- Orzech JW, Zatorska K, Grabowski M, et al. Preliminary results from the Polish Infective Endocarditis Registry (POL-ENDO): Time to change clinical practice? Kardiol Pol. 2024; 82(6): 609–616.
- Jędrzejczyk-Patej E, Mazurek M, Kowalski O, et al. Device-related infective endocarditis in cardiac resynchronization therapy recipients — Single center registry with over 2500 person-years follow up. Int J Cardiol. 2017; 227: 18–24.
- Jędrzejczyk-Patej E, Mazurek M, Kotalczyk A, et al. Upgrade from implantable cardioverter-defibrillator vs. de novo implantation of cardiac resynchronization therapy: long-term outcomes. Europace. 2021; 23(1): 113–122.
- Morawiec R, Matuszewska-Brycht O, Maeser P, et al. Decreasing numbers of valve-related infective endocarditis cases. An urgent call to action to improve diagnostic pathways: A retrospective tertiary center perspective (2015–2022). Kardiol Pol. 2024; 82(1): 79–81.
- Martínez-Sellés M, Muñoz P, Estevez A, et al. Long-term outcome of infective endocarditis in non-intravenous drug users. Mayo Clin Proc. 2008; 83(11): 1213–1217.
- Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 43(7): 561–632.
